Colgate-Palmolive Company (CL) P/E Ratio History
Historical price-to-earnings valuation from 1990 to 2025
Loading P/E history...
CL Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 6, 2026, Colgate-Palmolive Company (CL) trades at a price-to-earnings ratio of 33.5x, with a stock price of $88.16 and trailing twelve-month earnings per share of $2.65.
The current P/E is 11% above its 5-year average of 30.3x. Over the past five years, CL's P/E has ranged from a low of 22.4x to a high of 42.9x, placing the current valuation at the 75th percentile of its historical range.
Compared to the Consumer Defensive sector median P/E of 19.6x, CL trades at a 71% premium to its sector peers. The sector includes 149 companies with P/E ratios ranging from 0.0x to 193.7x.
Relative to the broader market, CL commands a significant premium over the S&P 500 median P/E of 25.2x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our CL DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
CL P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $346B | 22.7 | 4.07 | +8% | |
| $130B | 22.2 | 16.28 | -11% | |
| $33B | 16.3 | - | -20% | |
| $22B | 31.4 | - | +27% | |
| $1B | 5.7Lowest | 0.15Best | +538%Best | |
| $3B | 32.0 | 0.79 | -13% | |
| $2B | 22.0 | 1.70 | -6% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
CL Historical P/E Data (1990–2025)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q4 | Wed Dec 31 2025 00:00:00 GM | $79.02 | $2.62 | 30.1x | +1% |
| FY2025 Q3 | $79.94 | $3.57 | 22.4x | -25% | |
| FY2025 Q2 | Mon Jun 30 2025 00:00:00 GM | $90.90 | $3.56 | 25.5x | -14% |
| FY2025 Q1 | Mon Mar 31 2025 00:00:00 GM | $93.70 | $3.54 | 26.5x | -11% |
| FY2024 Q4 | $90.91 | $3.52 | 25.8x | -13% | |
| FY2024 Q3 | Mon Sep 30 2024 00:00:00 GM | $103.81 | $3.49 | 29.7x | +0% |
| FY2024 Q2 | Sun Jun 30 2024 00:00:00 GM | $97.04 | $3.45 | 28.1x | -5% |
| FY2024 Q1 | Sun Mar 31 2024 00:00:00 GM | $90.05 | $3.16 | 28.5x | -4% |
| FY2023 Q4 | Sun Dec 31 2023 00:00:00 GM | $79.71 | $2.78 | 28.7x | -3% |
| FY2023 Q3 | Sat Sep 30 2023 00:00:00 GM | $71.11 | $1.92 | 37.1x | +25% |
| FY2023 Q2 | Fri Jun 30 2023 00:00:00 GM | $77.04 | $1.80 | 42.9x | +44% |
| FY2023 Q1 | Fri Mar 31 2023 00:00:00 GM | $75.15 | $1.92 | 39.2x | +32% |
Average P/E for displayed period: 29.7x
Full CL Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See CL's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CL Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CL vs WMT
Side-by-side business, growth, and profitability comparison vs Walmart Inc..
Start ComparisonCL — Frequently Asked Questions
Quick answers to the most common questions about buying CL stock.
Is CL stock overvalued or undervalued?
CL trades at 33.5x P/E, near its 5-year average of 30.3x. The 75th percentile ranking places valuation within normal historical bounds.
How does CL's valuation compare to peers?
Colgate-Palmolive Company P/E of 33.5x compares to sector median of 19.6x. The premium reflects expected growth above peers.
What is CL's PEG ratio?
CL PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 1990-2025.